Wed, Aug 20, 2014, 8:46 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

CTI BioPharma Corp. Message Board

  • nndung802000 nndung802000 Nov 14, 2012 11:26 AM Flag

    Presentation in London, stock up 8% in Milan today

    European investors like this stock

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Just 1 months before:

      Tue Oct 2, 2012 8:53am EDT

      (Reuters) - Cell Therapeutics Inc said U.S. health regulators granted orphan drug status to its brain cancer drug.

      Orphan status, which is granted by the U.S. Food and Drug Administration to drugs that treat diseases affecting fewer than 200,000 people, provides seven years' marketing exclusivity from the date of approval.

      The designation was granted based on preliminary data from the mid-stage study of the drug, Opaxio, for treating glioblastoma multiforme (GBM), the company said.

      GBM is the deadliest and most common type of primary brain tumor in adults.

      It is estimated that there will be 10,000-12,000 new cases of GBM diagnosed in the United States this year alone, the company said, citing data from the National Cancer Institute.

      Company has 2 Products in phase III, 2 in phase II.
      Great potencial for this price. Stay long and you will get benefit.

      Sentiment: Strong Buy

      • 1 Reply to nndung802000
      • Pixuvri, CTICs lead therapeutic candidate has been sold in Europe.

        Pixuvri is the first approved treatment in the European Union in this patient setting. The decision cleared the way for CTI to market Pixuvri in the 27 Member States of the EU as well as in Iceland, Liechtenstein and Norway.

        The European market could generate up to $240 million in annual revenue, once the company is able to penetrate the market, and successful use overseas could also bolster the company's prospects for US approval.

        Sentiment: Strong Buy

2.55-0.01(-0.39%)Aug 20 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.